Hypertension is characterized by unclear etiology, prolonged disease duration, and incurability, ranking highest in prevalence among metabolic disorders. To alleviate patient burden, hypertension health management (HHM) was incorporated into National Essential Public Health Services Program (NEPHSP). However, patient follow-up rates remain substantially below expected levels. Digital therapeutics (DTx) deliver evidence-based therapeutic interventions through high-quality software programs to prevent, manage, or treat hypertension. This approach significantly enhances clinician-patient communication frequency and optimizes healthcare resource utilization efficiency. This study examines hypertension DTx products within the Digital Therapeutics Alliance (DTA) product library and published randomized controlled trials (RCTs) to explore application prospects in China. Findings indicate that China should draw on international DTx experiences for HHM, leverage socio-environmental factors to enhance stakeholder acceptance of DTx concepts, establish regulatory frameworks aligned with product characteristics, strengthen enterprise's research and development capabilities, and accelerate DTx advancement in hypertension management.